HCW Biologics vs Tscan Therapeutics
Tscan Therapeutics is the larger business, with $10.3m of revenue in fiscal 2025 against $54,232 for HCW Biologics (190.4 times as much). Tscan Therapeutics grew faster (266.7% against -97.9%). Tscan Therapeutics kept more of each dollar of sales as profit: a net margin of -1256.8% against -14677.1%. Tscan Therapeutics carries less debt relative to equity (26.4% against 246.3%).
| Latest fiscal year | HCW BiologicsHCWB, 2025 | Tscan TherapeuticsTCRX, 2025 |
|---|---|---|
| Revenue | $54,232 | $10.3m |
| Revenue growth | -97.9% | 266.7% |
| Net income | −$8.0m | −$130m |
| Operating margin | -24270.7% | -1315.4% |
| Net margin | -14677.1% | -1256.8% |
| Return on equity | — | -71.3% |
| Free cash flow | −$13.4m | −$140m |
| Cash | $2.0m | $152m |
| Total debt | $6.8m | $32.5m |
| Debt to equity | 246.3% | 26.4% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 35 | 142 |
| Market value | $1.5m | $24.4m |
| Price vs our value range | — | — |
| Moat score | 12 (Weak) | 12 (Weak) |
| Insider trades, 12 months | 6 buys, 0 sales | 3 buys, 0 sales |